HBP:CC - Helix BioPharma Corp. Announces Scientific Collaboration with University Hospital Tuebingen
(TheNewswire)
Toronto, Ontario – TheNewswire – August 9, 2022 – Helix BioPharmaCorp . (TSX:HBP) (OTC:HBPCF) (“Helix”or the “Company”), a clinical-stage biopharmaceutical company thatis developing unique therapies in the field of immuno-oncology basedon its proprietary technology platform DOS47, is pleased to announcethat it has entered into a two-year scientific collaboration agreement(“Agreement”) with University HospitalTuebingen (Germany) to assess the therapeuticresponse of L-DOS47 in several cancer models expressing CEACAM6, withadvanced preclinical metabolic imaging.
We aim to explore thepotential synergistic effects of L-DOS47 in combination withcheckpoint inhibitors on relevant cancer models. To accomplish thisoverarching aim, Helix established a two-year collaborativepartnership with a unique team from the University Hospital Tuebingento gain further insights into the effects of L-DOS47 on the tumormicroenvironment and pH modulation in vivo . Inaddition, the collaboration also explores the potential for designingnovel LDOS47-based radiotracers with application in translationalimmune-oncology and molecular imaging.
Mr. Artur Gabor, CEO of Helix, commented, “We areexcited to collaborate with the University Hospital of Tuebingen and especially the Medical Faculty, which haverelevant experience and knowledge in molecular imaging, particularlythe method of AcidoCEST, which makes pH changes in the tumormicroenvironment visible through a color change. We expect thiscollaboration to result in new and additional insight into thetherapeutic response of L-DOS47 in several not yet exploredpreclinical cancer models expressing CEACAM6.”
Prof. André F. Martins (Ph.D.,Department of Preclinical Imaging and Radiopharmacy) and Manfred Kneilling (MD, Department of Preclinical Imagingand Radiopharmacy & Department of Dermatology) of the Universityof Tuebingen said, “We are pleased to work with Helix on thisexciting project. Our technological advances combined with Helix’L-DOS47, which has already shown promising preclinical and clinicalsafety data, will allow us to gain further insights into its uniquemechanism of action. L-DOS47 might be in combination with immune checkpoint inhibitor-based immunotherapies and other targeted therapiesapplicable to promote tumors regression and thus to improve thetreatment efficacy and hopefully long-term survival.” Prof. Martinsand Kneilling are members of the “Image-Guided and FunctionallyInstructed Tumor Therapies” (iFIT) Cluster of Excellence at theUniversity of Tuebingen. iFIT is the only oncology-based cluster inGermany, a research consortium aiming to develop innovative andsustainable cancer therapies.
Helix BioPharma Corp. is a clinical-stagebiopharmaceutical company developing unique therapies in the field ofimmune-oncology for the prevention and treatment of cancer, based onthe proprietary technology platform DOS47. Helix is listed on the TSXunder the symbol “HBP.”
About University Hospital Tuebingen
Founded in 1805, the University Hospital Tuebingen is one ofthe leading centers of German university medicine. With its close tiesto the Medical Faculty of the University of Tuebingen, it is one of 35University Hospitals in Germany contributing to a successfulcombination of top-level medicine, research, and teaching. Its expertscollaborate across disciplines and offer state-of-the-art treatment tomore than 400,000 in- and outpatients worldwide each year.Neurosciences, Oncology and Immunology, Infection Biology, VascularMedicine, and Diabetes are focus areas of research at the MedicalFaculty of Tuebingen. https://www.medizin.uni-tuebingen.de/en-de/
About L-DOS47
L-DOS47 is Helix’s first immunoconjugate-based drugcandidate in development based on the Company’s novel DOS47 platformtechnology, which is designed to use an innovative approach to modifythe microenvironmental conditions of cancer cells in a manner thatleads to their destruction.
For more information, please contact:
Helix BioPharma Corp.
Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, CorporateSecretary
Forward-LookingStatements and Risks and Uncertainties
This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47, and statementsregarding expected improvements to the Company’s independence,diversification and corporate governance and the Company’sexpectations regarding strengthening its future growth capabilities.Forward-looking statements can further be identified by the use offorward-looking terminology such as “ongoing”, “estimates”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.
Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements,including financial outlooks, are intended to provide informationabout management’s current plans and expectations regarding futureoperations, including without limitation, future financingrequirements, and may not be appropriate for other purposes. Certainmaterial factors, estimates or assumptions have been applied in makingforward-looking statements in this news release.
The Company’s actual results coulddiffer materially from those anticipated in the forward-lookingstatements contained in this news release as a result of numerousknown and unknown risks and uncertainties, including withoutlimitation; the risk that the Company’s assumptions may prove to beincorrect; the risk that additional financing may not be obtainable ina timely manner, or at all, and that clinical trials may not commenceor complete within anticipated timelines or the anticipated budget ormay fail; third party suppliers of necessary services or of drugproduct and other materials may fail to perform or be unwilling orunable to supply the Company, which could cause delay or cancellationof the Company’s research and development activities; necessaryregulatory approvals may not be granted or may be withdrawn; theCompany may not be able to secure necessary strategic partner support;general economic conditions, intellectual property and insurancerisks; changes in business strategy or plans; and other risks anduncertainties referred to elsewhere in this news release, any of which could cause actualresults to vary materially from current results or the Company’santicipated future results. Certain of these risks and uncertainties,and others affecting the Company, are more fully described in theCompany’s annual management’s discussion and analysis for the yearended July 31, 2021 under the heading “Risks and Uncertainties”and Helix’s Annual Information Form, in particular under theheadings “Forward-looking Statements” and “Risk Factors”, andother reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time.Forward-looking statements and information are based on the beliefs,assumptions, opinions and expectations of Helix’s management on thedate of this new release, and the Company does not assume anyobligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.